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Recently we have demonstrated that sodium arsenite
induces the expression of hypoxia-inducible factor 1
(HIF-1) protein and vascular endothelial growth factor
(VEGF) in OVCAR-3 human ovarian cancer cells. We
now show that arsenic trioxide, an experimental anti-
cancer drug, exerts the same effects. The involvement of
phosphatidylinositol 3-kinase and mitogen-activated
protein kinase (MAPK) pathways in the effects of so-
dium arsenite was investigated. By using kinase inhibi-
tors in OVCAR-3 cells, both effects of sodium arsenite
were found to be independent of phosphatidylinositol
3-kinase and p44/p42 MAPKS but were attenuated by
inhibition of p38 MAPK. A role for p38 in the regulation
of HIF-1 and VEGF expression was supported further
by analysis of activation kinetics. Experiments in mouse
fibroblast cell lines, lacking expression of c-Jun N-ter-
minal kinases 1 and 2, suggested that these kinases are
not required for induction of HIF-1 protein and VEGF
mRNA. Unexpectedly, sodium arsenite did not activate a
HIF-1-dependent reporter gene in OVCAR-3 cells, indi-
cating that functional HIF-1 was not induced. In agree-
ment with this hypothesis, up-regulation of VEGF
mRNA was not reduced in HIF-1/ mouse fibroblast
cell lines. Altogether, these data suggest that not HIF-1,
but rather p38, mediates induction of VEGF mRNA ex-
pression by sodium arsenite.
Vasular Endothelial Growth Factor (VEGF)1 plays a key role
in tumor angiogenesis. VEGF occurs in at least six isoforms of
121, 145, 165, 183, 189, and 206 amino acids, which are gen-
erated from a single gene by alternative splicing (1). We have
reported that VEGF165 overexpression stimulates angiogenesis
in human ovarian cancer xenografts (2).
Elevated expression of VEGF in tumor cells can be the result
of environmental factors, such as hypoxia, or mutations in
oncogenes or tumor suppressor genes that regulate growth
factor signal transduction pathways (3–9). Many stimuli, in-
cluding hypoxia, growth factors, hormones, and oxidative stres-
sors, can increase VEGF expression in tumor cells in vitro (6,
10–14). In all mentioned cases, increased VEGF expression can
be caused in part by increased VEGF gene transcription medi-
ated by the transcription factor hypoxia-inducible factor-1
(HIF-1) (4–7, 11, 13–15). HIF-1 binds to a hypoxia-responsive
element (HRE) located within the VEGF promoter (11).
HIF-1 is composed of two subunits, HIF-1 and HIF-1. The
activity of HIF-1 is regulated mainly by the expression and
activity of the HIF-1 subunit. Although HIF-1 protein is
rather stable and readily detected in the nucleus of most nor-
moxic cells, HIF-1 protein is often hardly detectable because
of rapid degradation by the ubiquitin-proteasome system (16–
18). Hypoxia increases the level of HIF-1 protein by inhibiting
its ubiquitination and degradation (19). Accumulation of
HIF-1 protein can also be observed in stimulated normoxic
cells (5, 8, 9, 13–15). HIF-1 is subsequently translocated to the
nucleus, where it can dimerize with HIF-1 to form the HIF-1
complex (20). To be fully active, HIF-1 requires interaction(s)
with coactivators or/and transcription factor(s) (20–23). The
activated protein-1 transcription factor family member c-Jun
interacts with HIF-1 and is suggested to cooperate with HIF-1
in the induction of VEGF expression by hypoxia (23).
The stabilization and transcriptional activation of the
HIF-1 protein involve changes in its phosphorylation state.
Activation of the lipid kinase phosphatidylinositol 3-kinase
(PI3K), and/or its downstream target the protein-serine/threo-
nine kinase Akt, can result in the phosphorylation and stabi-
lization of HIF-1 under hypoxic and normoxic conditions (8,
24). In addition, inhibition of PI3K activity has been shown to
reduce the transactivation function of HIF-1 in hypoxic cells
(25). So far, there is no evidence that PI3K and Akt can phos-
phorylate HIF-1 directly. Other pathways that regulate
HIF-1 phosphorylation involve members of the mitogen-acti-
vated protein kinase (MAPK) family (26). In hypoxic and in
stimulated normoxic cells, p44/p42 MAPK (extracellular sig-
nal-regulated kinase (ERK)-1 and ERK-2) and p38 MAPK en-
hance the transactivation function of HIF-1 (24, 25, 27). This
may occur through direct phosphorylation because these ki-
nases have been shown to phosphorylate HIF-1 in vitro (28,
29). In some cases, p44/p42 MAPK and p38 can also influence
HIF-1 protein induction (8, 30). The stress-activated protein
kinases/c-Jun N-terminal kinases (SAPKs/JNKs) do not phos-
phorylate HIF-1 in vitro, but may indirectly regulate HIF-1-
mediated transcription of VEGF under hypoxia through phos-
phorylating the transcription factor c-Jun (18, 23).
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The stabilization and transcriptional activation of HIF-1
may also involve alterations in its redox state. Evidence is
provide that changes in the levels of reactive oxygen species
(ROS) may play a role in HIF-1 protein induction and HIF-1
transactivation (14, 30–32). Increased levels of ROS are sug-
gested to mediate PI3K activation under hypoxia as well as
under normoxia (32, 33). The levels of ROS may also directly or
indirectly influence the redox status of cysteine residues in the
transactivation domains of HIF-1, which can affect interac-
tions with transcriptional coactivators (21, 22).
In a previous study on the role of oxidative stress in the
regulation of VEGF, we showed that sodium arsenite (NaAsO2)
induces HIF-1 protein and VEGF mRNA and protein levels in
the human ovarian cancer cell lines OVCAR-3 and H134 (34).
Arsenite induces oxidative stress by binding to thiol groups of
cellular proteins and by increasing the production of ROS.
Because the effects of sodium arsenite on HIF-1 protein and
VEGF expression are independent of increased ROS produc-
tion, we hypothesized that they may be mediated through
binding of arsenite to thiol (SH) groups of the HIF-1 protein
itself or of components of signal transduction pathways in-
volved in HIF-1 or VEGF regulation (34).
Our findings with sodium arsenite may be of clinical rele-
vance. Several cytotoxic agents in cancer treatment are suscep-
tible of interacting with thiol groups of cellular proteins. More-
over, arsenic trioxide (As2O3), another trivalent arsenic
compound, has potential as an anticancer agent (35). At low
dosages (1–10 M), arsenic trioxide has a significant cytotoxic
effect on human ovarian cancer cell lines and is suggested to be
a useful agent for the treatment of ovarian cancer (36). There-
fore, we now compared the potency of arsenic trioxide with that
of sodium arsenite to induce HIF-1 protein and VEGF mRNA
and protein levels in the OVCAR-3 human ovarian cancer cell
line. We also investigated the role of the PI3K/Akt pathway and
of MAPK family members in sodium arsenite-induced HIF-1
protein accumulation and VEGF expression. Furthermore, we
examined whether up-regulation of VEGF mRNA expression
by sodium arsenite was mediated by HIF-1.
EXPERIMENTAL PROCEDURES
Chemicals—Sodium arsenite, arsenic trioxide, wortmannin, gluta-
thione (GSH), N-acetylcysteine (NAc), and buthionine-sulfoximine
(BSO) were purchased from Sigma. PD98059, SB203580 and SB202190
were purchased from Calbiochem.
Cell Culture and Cell Treatment—OVCAR-3 human ovarian cancer
cells and Jnk1/ Jnk2/, Jnk1/Jnk2/, HIF-1/, and HIF-1/
mouse fibroblasts were cultured in Dulbecco’s modified Eagle’s medium
(Invitrogen) supplemented with 10% heat-inactivated fetal calf serum
(Sanbio, Uden, The Netherlands), 50 units/ml penicillin (ICN Biochemi-
cals, Zoetermeer, The Netherlands), and 50 g/ml streptomycin (ICN
Biochemicals). Cells were routinely cultured in 95% air and 5% CO2 at
37 °C. Hypoxic conditions were performed by incubation of cells in a
tightly sealed chamber maintained at 1% oxygen, 94% N2, and 5% CO2
at 37 °C. Immortalized Jnk1  Jnk2/ and Jnk1/ Jnk2/ cell lines
were kindly provided by Dr. E. F. Wagner (Research Institute of Mo-
lecular Pathology, Vienna, Austria). These cell lines have been estab-
lished independently from individual primary mouse embryo fibro-
blasts that were each isolated from a single mouse embryo following the
3T3 protocol (37, 38). Immortalized HIF-1/ and HIF-1/ cell lines
were kindly provided by Dr. G. L. Semenza (Johns Hopkins University
School of Medicine, Baltimore, MD). Both cell lines were established by
transfection of primary mouse embryo fibroblast cultures with an ex-
pression vector encoding simian virus 40 T-antigen as described else-
where (39).
For treatment of cells with sodium arsenite or arsenic trioxide, cells
were seeded in culture dishes in medium and grown overnight. There-
after, sodium arsenite or arsenic trioxide was added to the conditioned
medium, and cells were incubated further for the time periods as
indicated in each experiment. Pretreatment of cells with wortmannin,
PD98059, SB203580, SB202190, GSH, and NAc was performed for 1 h
before the addition of sodium arsenite; pretreatment with BSO was
performed for 16 h.
Antibodies—Rabbit polyclonal antisera directed against phospho-
Akt-1 (Ser473), phospho-p44/p42 MAPK (Thr202/Tyr204), phospho-SAPK/
JNK (Thr183/Tyr185), phospho-p38 MAPK (Thr180/Tyr182), phospho-c-
Jun (Ser73), p44/p42 MAPK, SAPK/JNK, p38 MAPK, and a horseradish
peroxidase-coupled anti-rabbit antiserum were purchased from New
England Biolabs. Mouse monoclonal antisera to HIF-1 were purchased
from Novus Biologicals/AbCam (Cambridge, U. K.) and BD Transduc-
tion Laboratories (Alphen a/d Rijn, The Netherlands). The sheep poly-
clonal antiserum directed against Akt-1 was from Upstate Biotechnol-
ogy Inc. Rabbit polyclonal antisera directed against c-Jun (H-79) and
Raf-1 (C12) were purchased from Santa Cruz Biotechnology. The mouse
monoclonal antiserum against -actin (C4) was purchased from Roche
Molecular Biochemicals. The polyclonal human antiserum against to-
poisomerase I was purchased from TopoGEN (Columbus, OH). The
mouse monoclonal antiserum against human p53 (DO-7) and the horse-
radish peroxidase-coupled anti-mouse serum were purchased from
DAKO (Glostrup, Denmark). The horseradish peroxidase-coupled anti-
sheep serum was purchased from Calbiochem.
Preparation of Cell Extracts for Western Blot Analysis and ELISA—
Cells were washed once with ice-cold phosphate-buffered saline and
lysed by scraping with a rubber policeman in 250 l of radioimmune
precipitation assay buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1%
SDS, 1% Nonidet P-40, and 1% sodium deoxycholate) for Western
blotting or in 450 l of E1A buffer (50 mM Tris-HCl, pH 7.5, 250 mM
NaCl, 5 mM EDTA, and 0.1% Nonidet P-40) for ELISA. Both lysis
buffers were supplemented with 50 mM NaF, 1 mM Na3VO4, 1.0 mM
phenylmethylsulfonyl fluoride, 0.5 mM trypsin inhibitor, and 0.5 g/ml
leupeptin. After a 15-min incubation period on ice, the extracts were
clarified by centrifugation at 14,000 rpm for 15 min at 4 °C and stored
at 70 °C. Isolation of nuclear and cytoplasmic protein fractions from
OVCAR-3 cells in the subcellular fractionation experiment was per-
formed as described previously (40). Protein concentrations were deter-
mined by the Coomassie Plus Protein assay (Pierce).
Western Blotting—Equal amounts of protein cell extracts were re-
solved in SDS-polyacrylamide gels and transferred electrophoretically
onto a polyvinylidene difluoride membrane (Immobilon). Membranes
were blocked for 1 h in TBST (10 mM Tris, pH 8.0, 150 mM NaCl, and
0.025% Tween 20) and 5% milk and incubated overnight with anti-
serum directed against phospho-Akt-1(1:3,000), phospho-p44/p42
MAPK (1:1,000), phospho-SAPK/JNK (1:1,000), phospho-p38 (1:1,000),
phospho-c-Jun (1:1,000), HIF-1 (1:500), -actin (1:2,000), Raf-1 (1:
500), topoisomerase I (1:5,000) or p53 (1:1,000). After washing with
TBST, the membranes were incubated for 1 h with horseradish perox-
idase-linked anti-rabbit or anti-mouse antiserum in TBST and 5% milk.
The membranes were washed again with TBST, and proteins were
visualized by enhanced chemiluminescence. To detect both nonphos-
phorylated and phosphorylated forms of Akt-1, c-Jun, and the MAPK
family members, membranes were stripped for 15 min in strip buffer
(10 mM Tris, pH 8.0, 2% SDS, 10 mM -mercaptoethanol) at 42 °C and
washed with TBST. Subsequently, the blots were blocked again and
incubated for 2 h with Akt-1, p44/p42 MAPK, SAPK/JNK, or p38-
specific antiserum (1:1,000 dilution) or with a c-Jun-specific antiserum
(1:500 dilution) in TBST and 5% milk. The incubations with horserad-
ish peroxidase-linked anti-rabbit, anti-mouse, and anti-sheep antisera
and the detection of the proteins were performed as described above.
ELISA—Equal numbers of cells were plated on 9.6-mm culture
dishes and grown overnight. The conditioned medium of all dishes was
collected, pooled, and 450 l was sampled (time-point (T)  0 medium
sample). Cells of one dish were washed and lysed in 450 l of lysis
buffer as described above (T  0 lysate sample). The conditioned me-
dium was divided into 5 volumes. Sodium arsenite was added to 1
volume at a concentration of 100 M, and arsenic trioxide was added to
3 volumes at concentrations of 100, 50, and 10 M. Subsequently,
conditioned medium with or without sodium arsenite or arsenic trioxide
was again added to culture dishes with cells. Thus, at T 0 the amount
of VEGF protein in the medium was the same in each culture dish. Cells
were incubated further for the time periods indicated in each experi-
ment. Thereafter, 450 l of conditioned medium was sampled, and cells
were lysed. VEGF concentrations in nondiluted media samples and
lysates were determined in duplicate by ELISA using the reagents and
the protocol supplied with the Quantikine Human VEGF Immunoassay
kit (R&D Systems). Differences in VEGF concentrations in medium and
lysates of nontreated versus sodium arsenite- or arsenic trioxide-treated
cells were evaluated using Student’s t test for two groups. p values
0.05 were considered to be significant.
RNase Protection Assay—Generation of human -actin and VEGF165
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antisense probes has been described elsewhere (34). pcDNA3 vectors
(Invitrogen) containing a fragment of murine VEGF164 or -actin cDNA
were used as templates for the synthesis of murine VEGF164 and -actin
antisense probes. The templates were generated as follows. Total RNA
from Jnk1/ Jnk2/ mouse fibroblasts was reversed transcribed us-
ing Moloney murine leukemia virus reverse transcriptase (Invitrogen).
Murine VEGF164 cDNA (nucleotides 454–648) was amplified with the
forward primer 5-ATAACAAGCTTAGCACAGCAGATGTGAATGC-3
and the reversed primer 5-GCAACCTCGAGCTTGTCACATCTGCAA-
GTAC-3. Murine -actin cDNA (nucleotides 630–780) was amplified
with the forward primer 5-ATAACAAGCTTGCTATGTTGCCCTGGA-
TTTTGAG-3 and the reversed primer 5-GCAACCTCGAGGGA AGG-
AAGGCTGGAAGAGT-3. Amplification of VEGF164 and -actin cDNA
fragments was performed for 36 cycles at 94 °C, 56 °C, and 72 °C. In
addition to VEGF164 or -actin sequences (underlined), the forward and
reverse primers contain restriction sites (bold) for HindIII and XhoI,
respectively. The 216-nucleotide VEGF164 and 172-nucleotide -actin
amplified fragments were extracted with phenol/chloroform, precipi-
tated, dissolved in water, and digested with HindIII and XhoI. The
digestion mixtures were subjected to gel electrophoresis, and the
VEGF164 and -actin cDNA fragments were isolated from the agarose
gel by use of the QIAquick gel extraction kit (Qiagen). The isolated
VEGF164 and -actin cDNA fragments were cloned into the HindIII and
XhoI restriction sites of pcDNA3, and the sequence of the VEGF164 and
-actin cDNA fragments was verified by sequencing. pcDNA3VEGF164
and pcDNA3-actin were linearized with HindIII, and 228-nucleotide
VEGF164 and 185-nucleotide -actin antisense probes were generated
with SP6 polymerase.
The RNase protection assay was carried out as described (34). Hy-
bridization of total RNA to a 136-nucleotide human -actin antisense
probe gives rise to a protected fragment of 130 nucleotide, whereas
hybridization to the 185-nucleotide murine -actin antisense probe is
expected to result in the protection of a fragment of 151 nucleotides. It
should be noted that hybridization of total RNA to the 301-nucleotide
human VEGF165 antisense probe and the 228-nucleotide murine
VEGF164 can give rise to fragments of different sizes because of protec-
tion by VEGF mRNAs of different isoforms (1, 34, 41, 42). Protection by
human VEGF165 mRNA and murine VEGF164 mRNA is most efficient,
giving rise to protected fragments of 252 and 195 nucleotides, respec-
tively. Therefore, effects on VEGF mRNA levels were monitored by
assessing the mRNA levels of human VEGF165 and murine VEGF164.
Plasmid Constructs—The pGL3 promoter vector was purchased from
Promega. This vector contains the SV40 basal promoter upstream of
luciferase coding sequences and the SV40 late polyadenylation signal.
5xHREpGL3 contains five copies of a HIF-1 consensus sequence of the
human VEGF promoter and was cloned from the reporter plasmid
5HRE/hCMVmp (43). 5HRE/hCMVmp was digested with KpnI and
BglII, and the KpnI-BglII fragment was ligated into the KpnI-BglII-
digested pGL3-promoter vector. 5xjun2pGL3 contains five copies of the
jun2 element of the human c-jun promoter (44) and was constructed by
ligation of the PvuII-BglII fragment of the 5xjun2-tata-luciferase re-
porter construct (45) in the SmaI-BglII-digested pGL3 promoter vector.
Transient Transfection and Luciferase Assay—OVCAR-3 cells were
seeded on six-well culture plates and grown overnight in medium.
Transfection of OVCAR-3 cells with luciferase reporter constructs was
performed in duplicate wells by the calcium-phosphate precipitation
method (46). After a 6-h incubation period with the precipitate, the cells
were washed and refed with culture medium. 40 h later, cells were left
untreated or exposed to sodium arsenite or hypoxia for 6 h. Cells were
washed with phosphate-buffered saline and lysed in 250 l of lysis
reagent (25 mM Tris phosphate, pH 7.8, 2 mM dithiothreitol, 2 mM
CDTA, 10% glycerol, 1% Triton X-100). Protein concentrations were
determined by the Coomassie Plus Protein assay and -galactosidase
activity was assessed as described by Sambrook et al. (47). Luciferase
activity was determined by mixing 30 l of cell extract with 100 l of
luciferase assay reagent (Promega) and subsequent measurement of
relative light units for 10 s in a luminometer (Lumat LB 9507, EG&G
Berthold, Bad Wildbad, Germany). The mean relative luciferase activ-
ity was calculated as the mean luciferase activity (relative light units)/
-galactosidase (A420/g of protein/min) of duplicate extracts.
RESULTS
High Concentrations of Arsenic Compounds Induce HIF-1
Protein and VEGF Expression in OVCAR-3 Cells—We com-
pared the effects of different concentrations of arsenic trioxide
with those of sodium arsenite on HIF-1 protein, VEGF mRNA,
and VEGF protein expression in OVCAR-3 cells (Fig. 1). As can
be seen in Fig. 1A, high concentrations of arsenic trioxide (100
and 50 M) could indeed induce HIF-1 protein after 4 and 8 h
in OVCAR-3 cells, but to a much lesser extent than an equimo-
lar concentration of sodium arsenite (100 M). We also tested
the effect of 8- and 24-h exposure periods to 10 M arsenic
trioxide. This treatment did not induce detectable changes in
HIF-1 protein expression in OVCAR-3 cells.
The effects of arsenic trioxide on VEGF mRNA expression
were assessed by the RNase protection assay (Fig. 1B). As
determined by measurement of the signal intensities of the
252-nucleotide VEGF165- and 130-nucleotide -actin-protected
fragments, VEGF165 mRNA levels in OVCAR-3 cells were in-
creased 3- and 5-fold after 4 and 8 h of exposure to 100 M
arsenic trioxide, respectively. A 2- and 3-fold increase in
VEGF165 mRNA expression was observed after 4 and 8 h of
exposure to 50 M arsenic trioxide. An 8-h exposure period to
low concentrations of arsenic trioxide (10 M) did not influence
the level of VEGF165 mRNA, whereas a weak elevation (1.5-
fold) was observed after 24 h of exposure. In agreement with
the effects on HIF-1 protein, arsenic trioxide at 100 M was a
less potent inducer of VEGF165 mRNA than sodium arsenite.
100 M sodium arsenite increased the level of VEGF165 mRNA
up to 6- and 7-fold after 4 and 8 h of exposure.
We next assessed whether induction of VEGF mRNA levels
by arsenic trioxide resulted in an increased production of
VEGF protein. OVCAR-3 cells were grown overnight, and ar-
senic trioxide and sodium arsenite were added to the condi-
tioned medium. VEGF concentrations in the conditioned me-
dium or in cell lysates of treated and nontreated cells were
measured by ELISA. As can be seen in Fig. 1C, VEGF protein
levels in the conditioned medium were increased significantly
after 8 h of exposure to 100 and 50 M of arsenic trioxide
compared with the levels in the medium of control cells (p 
0.05). In the lysates, increased production of VEGF was evident
after 4 h of incubation and was more pronounced after 8 h (p 
0.05). As expected, a higher increase in VEGF protein concen-
trations in conditioned medium and lysate was observed after
treatment with 100 M sodium arsenite. Note that a weak
elevation of VEGF protein levels was detected in conditioned
medium and lysate of cells that were exposed to 10 M arsenic
trioxide for 24 h. These results clearly show that arsenic triox-
ide induces HIF-1 protein accumulation and VEGF expres-
sion in OVCAR-3 cells, albeit less potently than sodium arsen-
ite. In addition, these results indicate that long exposure to a
low, clinically relevant concentration of arsenic trioxide can
weakly increase VEGF165 mRNA and protein expression in the
absence of a detectable change in the level of HIF-1 protein
expression.
Induction of HIF-1 Protein and VEGF Expression by So-
dium Arsenite Is Not Mediated through PI3K—Because it has
been suggested that sodium arsenite can activate PI3K in some
cell types, we investigated the role of this pathway in sodium
arsenite-induced HIF-1 protein accumulation and VEGF ex-
pression in OVCAR-3 cells (48). PI3K-mediated activation of
Akt-1, the most frequently studied isoform of Akt, involves
phosphorylation on its amino acid residues Ser473 and Thr308.
We first monitored the phosphorylation of Akt-1 upon sodium
arsenite treatment in OVCAR-3 cells by Western blotting with
an antiserum recognizing Ser473-phosphorylated Akt-1. As can
be seen in Fig. 2A, OVCAR-3 cells showed a relatively high
basal level of phospho-Akt-1. After 15 min of exposure to 100
M sodium arsenite, Akt-1 phosphorylation on Ser473 was in-
creased, which was sustained until at least 4 h of exposure.
After 8 h, the levels of phospho-Akt-1 were decreased to basal.
The same results were obtained with an antiserum directed
against Thr308 (data not shown). The levels of total Akt-1 were
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unchanged upon sodium arsenite treatment for up to 8 h. We
examined further the involvement of PI3K in sodium arsenite-
induced Akt-1 phosphorylation by assessing the effects of the
PI3K inhibitor wortmannin. Fig. 2B shows that pretreatment
with 100 nM wortmannin completely blocked induction of Akt-1
phosphorylation by sodium arsenite. Wortmannin alone did not
significantly affect the basal level of phospho-Akt-1. Again, the
total levels of Akt-1 protein remained constant. These results
suggest that sodium arsenite indeed activates the PI3K/Akt-1
pathway in OVCAR-3 cells.
We next investigated the effect of wortmannin on sodium
arsenite-induced HIF-1 protein accumulation by analyzing
HIF-1 protein levels in the extracts of Fig. 2A by Western blot.
In sharp contrast to the phosphorylation of Akt-1, induction of
HIF-1 protein by sodium arsenite was completely unaffected
by 100 nM wortmannin (Fig. 2C). Pretreatment with wortman-
nin concentrations as high as 500 nM only weakly inhibited
HIF-1 protein accumulation. Analysis of total RNA by the
RNase protection assay in parallel samples revealed that nei-
ther sodium arsenite-induced VEGF165 mRNA levels nor the
basal VEGF165 mRNA levels in OVCAR-3 cells were influenced
by pretreatment with 100 and 500 nM concentrations of wort-
mannin (Fig. 2D). These results strongly suggest that induc-
tion of HIF-1 protein and VEGF expression by sodium arsen-
ite is independent of the PI3K/Akt-1 pathway in OVCAR-3
cells.
Sodium Arsenite activates p44/p42 MAPK, SAPK/JNK, and
p38 with Different Kinetics in OVCAR-3 Cells—Depending on
the cell type, sodium arsenite can activate different MAPK
family members (49), which may contribute to HIF-1 protein
accumulation and VEGF expression. Therefore, we first moni-
tored the activity of p44/p42 MAPK, SAPK/JNK, and p38 upon
sodium arsenite treatment in OVCAR-3 cells by detection of
their phosphorylated, activated forms on Western blots.
As can be seen in Fig. 3, nonstimulated OVCAR-3 cells
showed strong phosphorylation of p42/p44 MAPK. This is con-
sistent with a previous study reporting a high basal activity of
p44/p42 MAPK in these cells (50). A weak increase in the
phosphorylation of p44/p42 MAPK was observed as early as 5
min after the addition of 100 M sodium arsenite and remained
FIG. 1. Effect of sodium arsenite and trivalent arsenic on the levels of HIF-1 protein, VEGF165 mRNA, and VEGF165 protein in
OVCAR-3 cells. OVCAR-3 cells were exposed to 100 M sodium arsenite or to 100, 50, or 10 M arsenic trioxide for the indicated time periods.
After collection of conditioned medium, cells were lysed, and protein and total RNA were extracted. A, HIF-1 protein levels were assessed by
subjecting 100 g of protein to SDS-gel electrophoresis (7.5% gel) followed by Western blotting with a HIF-1-directed antiserum. An unidentified
protein that is nonspecifically recognized by the HIF-1-directed antiserum or by the secondary horseradish peroxidase-linked antiserum is
indicated as NS. B, VEGF165 mRNA levels were assessed by the RNase protection assay. Total RNA was hybridized to human VEGF165 and -actin
antisense probes. t-RNA (lane T) was hybridized as a negative control. The 252- and 130-nucleotide fragments protected by the mRNAs of VEGF165
and -actin and the full-length probes are indicated. The histogram indicates the relative VEGF165 mRNA expression in sodium arsenite or arsenic
trioxide-treated OVCAR-3 cells in which nontreated controls (T  0) were set at 100%. C, VEGF165 protein concentrations in conditioned media
(left panel) and lysates (right panel) of sodium arsenite or arsenic trioxide-treated OVCAR-3 cells were determined by ELISA. As a control, VEGF
protein concentrations were also measured in conditioned media and lysates of nontreated cells. The histograms represent the mean  S.D. of
duplicate samples in a representative experiment. Significant differences in mean VEGF concentrations in medium and lysates of nontreated
versus sodium arsenite or arsenic trioxide-treated cells after individual incubation periods are indicated by an asterisk (p 0.05). Results of sodium
arsenite and arsenic trioxide as shown in A, B, and C were assessed in parallel in one experiment that was representative of three independent
ones giving comparable results.
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detectable until at least 1 h of exposure. The phosphorylation of
both kinases returned to basal levels after 2 h and was even
reduced to lower levels after 4 and 8 h. Sodium arsenite also
induced the activity of JNK1, JNK2, and p38, albeit with dif-
ferent kinetics. A strong increase in the phosphorylation of
JNK1, JNK2, and p38 was observed after 1 h of sodium arsen-
ite treatment, and increased phosphorylation of all three ki-
nases was prolonged until at least 8 h of treatment. Changes in
phosphorylation of p42/p44 MAPK, JNK1, JNK2, and p38 were
not accompanied by alterations in the levels of these proteins.
These data indicate that sodium arsenite activates p44/p42
MAPK, JNK1, JNK2, as well as p38 with different kinetics in
OVCAR-3 cells. Activation of p44/p42 MAPK occurred rapidly
but was only moderate and transient. In contrast, activation
of JNK1, JNK2, and p38 was slower but more potent and
sustained.
Sodium Arsenite-induced HIF-1 Protein Accumulation and
VEGF Expression Are Attenuated by Inhibitors of p38 MAPK
Activity—To examine further the involvement of p44/p42
MAPK and p38 in the induction of HIF-1 protein and VEGF
expression by sodium arsenite, we analyzed the effect of the
kinase inhibitors PD98059, SB202190, and SB203580 in
OVCAR-3 cells. PD98059 is a specific inhibitor of MAPK/ERK
kinase (MEK)-1 and MEK-2, which phosphorylate and activate
p44/p42 MAPK. SB202190 and SB203580 directly inhibit the
activity of p38 by binding to its ATP binding domain.
Fig. 4, A–C, shows that induction of HIF-1 protein and
VEGF165 mRNA expression after 4 and 8 h of exposure to 100
M sodium arsenite was slightly, but not significantly, reduced
by pretreatment with high concentrations of PD98059 (50 M).
The basal level of HIF-1 protein and VEGF165 mRNA was also
hardly affected by this agent. PD98058 was functional in in-
hibiting p44/p42 MAPK activity at the concentrations used, as
demonstrated by the reduced level of phospho-p44/p42 MAPK
in the presence and absence of sodium arsenite (Fig. 4D). In
fact, phospho-p44/p42 MAPK levels were even below basal and
hardly detectable after 4 and 8 h of sodium arsenite and
PD98059. These data indicate that p44/p42 MAPK does not
regulate induction of HIF-1 protein and VEGF expression in
OVCAR-3 cells.
Pretreatment with the p38 inhibitors SB202190 and
SB203580 could potently inhibit induction of HIF-1 protein
and VEGF mRNA expression by sodium arsenite (Fig. 4, A–C).
As assessed at 4 and 8 h after the addition of 100 M sodium
arsenite, both effects were almost completely attenuated by a
20 M concentration of each inhibitor. Significant inhibition of
HIF-1 protein accumulation and VEGF mRNA expression
was also observed by pretreatment with 5 M SB202190 (data
not shown) and SB203580 (Fig. 4, A–C). Treatment with the
two inhibitors alone did not significantly influence the basal
level of HIF-1 protein and VEGF165 mRNA in OVCAR-3.
In some cell types, high concentrations (20–100 M) of
SB202190 or/and SB203580 can inhibit the activity of JNKs
(51). Activated JNKs are known to enhance the activity of the
transcription factor c-Jun through the phosphorylation of two
serine residues at positions 63 and 73 (26). To examine whether
JNK activity was influenced by SB203580 in sodium arsenite-
treated OVCAR-3 cells, we analyzed the phosphorylation of
c-Jun on Ser73 and the total level of c-Jun by Western blotting.
Fig. 4E shows that phosphorylated c-Jun proteins were not
detectable in nonstimulated OVCAR-3 cells. After 2 h of so-
dium arsenite treatment, phosphorylation of c-Jun protein was
clearly observed and was increased further until at least 8 h of
exposure. Consistent with findings that phosphorylation on
Ser63 and Ser73 decreases the electrophoretic mobility of the
c-Jun protein (52), slower migrating forms of c-Jun were de-
tectable after sodium arsenite treatment. The total level of
c-Jun protein was also increased by sodium arsenite. Pretreat-
ment with 20 M SB203580 did not prevent the phosphoryla-
tion of c-Jun on Ser73 in OVCAR-3 cells upon exposure to
sodium arsenite (Fig. 4E). Hyperphosphorylated, retarded c-
Jun protein band(s) were clearly detectable. The observed de-
FIG. 2. Effect of wortmannin on sodium arsenite-induced
Akt-1 phosphorylation, HIF-1 protein accumulation, and
VEGF expression in OVCAR-3 cells. OVCAR-3 cells were exposed to
100 M sodium arsenite in the absence or presence of 100 or 500 nM
wortmannin or to 100 or 500 nM wortmannin alone. Wortmannin was
added 1 h before the addition of sodium arsenite. After the indicated
periods of exposure to sodium arsenite, cells were lysed, and protein and
total RNA were extracted. A and B, the phosphorylation of Akt-1 was
monitored by subjecting 100 g of protein to SDS-gel electrophoresis
(8% gel) followed by Western blotting with an antiserum specific to
Ser(P)473. The blots were stripped and reprobed with a total Akt-1
antiserum. C, HIF-1 protein levels were examined by subjecting 100
g of protein to SDS-gel electrophoresis (7.5% gel) followed by Western
blotting with a HIF-1-directed antiserum. D, VEGF165 mRNA levels
were analyzed by RNase protection as in B.
FIG. 3. Effect of sodium arsenite on the phosphorylation of
MAPK family members in OVCAR-3 cells. OVCAR-3 cells were
exposed to 100 M sodium arsenite for the indicated time periods. 25 g
of protein was subjected to SDS-gel electrophoresis (10% gel) and West-
ern blotting. Phosphorylation of p44/p42 MAPK, JNK1/2 (p46, p54), and
p38 was detected using phospho-antisera. The blots were stripped and
reprobed with antisera recognizing both nonphosphorylated and phos-
phorylated forms of p44/p42 MAPK, JNK1/2 (p46, p54), and p38.
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crease in the level of phospho-c-Jun protein is more likely the
result of an inhibitory effect of SB203580 on sodium arsenite-
induced c-Jun protein expression instead of inhibition of c-Jun
phosphorylation. Pretreatment with 5 M SB203580 did also
not affect c-Jun phosphorylation and had only a minor effect on
c-Jun protein levels. These results support that attenuation of
sodium arsenite-induced HIF-1 protein accumulation and
VEGF mRNA expression by SB203580 is specific and exclude
the possibility that this is caused by a toxic effect of this
inhibitor on OVCAR-3 cells. In addition, these data indicate
that SB203580 does not influence JNK activity in sodium ar-
senite-treated OVCAR-3 cells at the concentrations used.
Therefore, our results with SB203580 and SB202190 strongly
suggest that induction of HIF-1 protein and VEGF expression
by sodium arsenite is mediated by p38 in OVCAR-3 cells.
Activation of p38 MAPK and Induction of HIF-1 Protein by
Sodium Arsenite Are Co-modulated by the Level of Intracellular
GSH—We have shown previously that the level of intracellular
GSH is critical for induction of HIF-1 protein and VEGF
expression by sodium arsenite in OVCAR-3 cells (34). Pretreat-
ment with agents that elevate intracellular GSH levels, such as
GSH and NAc (a precursor of GSH), attenuate sodium arsenite-
induced HIF-1 accumulation and VEGF expression, whereas
depletion of intracellular GSH by pretreatment with BSO po-
tentiates both effects (34). The latter agent causes GSH deple-
tion by inhibiting -glutamylcysteine synthetase, an enzyme
involved in the synthesis of GSH (53).
In light of our findings with the p38 inhibitors that p38 may
be an upstream regulator of HIF-1 protein and VEGF expres-
sion, we assessed whether activation of p38 by sodium arsenite
was also modulated by exposure to GSH, NAc, and BSO prior to
the addition of sodium arsenite in OVCAR-3 cells. As a control,
the level of the HIF-1 protein was analyzed in parallel in the
same extracts. Fig. 5A shows that pretreatment with 10 and 20
mM GSH and NAc almost completely attenuated sodium arsen-
ite-induced phosphorylation of p38 in OVCAR-3 cells. Differ-
ences in the signal of the phospho-p38 band were not caused by
changes in the total level of p38 because these remained almost
constant under all circumstances. The basal level of p38 phos-
phorylation appeared not to be influenced by pretreatment
with 20 mM concentrations of the antioxidants alone. In agree-
ment with our previous findings (34), GSH and NAc pretreat-
ment also attenuated HIF-1 protein induction, whereas a
minor effect was observed on the basal level of HIF-1 protein.
To examine the effect of GSH depletion on p38 phosphoryl-
ation, OVCAR-3 cells were pretreated with 500 M BSO for
16 h before the addition of a lower, suboptimal concentration of
sodium arsenite (30 M). Because sodium arsenite reduces in-
tracellular GSH levels by itself, the effect of BSO is more
pronounced when OVCAR-3 cells are exposed to a suboptimal
concentration of this agent. Fig. 5B shows that pretreatment
with BSO clearly potentiated the phosphorylation of p38 after
4, 6, and 8 h of exposure to sodium arsenite, without affecting
the total levels of this protein. Pretreatment with 500 M BSO
alone for a period of 24 h hardly affected the basal levels of p38
phosphorylation. It should be mentioned that potentiation of
p38 activity in the presence of BSO was already observed after
4 h, whereas potentiation of HIF-1 protein accumulation was
not detected until 6 h of exposure to sodium arsenite. Thus, the
p38 response in GSH-depleted OVCAR-3 cells upon sodium
arsenite treatment precedes the response of HIF-1. This re-
jecting 100 g of protein to SDS-gel electrophoresis (10% gel) followed
by Western blotting with an antiserum specific to Ser(P)73. The blot was
stripped and reprobed with an antiserum recognizing both nonphospho-
rylated and phosphorylated forms of c-Jun.
FIG. 4. Effect of kinase inhibitors on sodium arsenite-induced
HIF-1 protein and VEGF mRNA levels in OVCAR-3 cells.
OVCAR-3 cells were exposed to 100 M sodium arsenite in the absence
or presence of the kinase inhibitors PD98059 (50 M), SB202190 (20
M), and SB203580 (20 and 5 M) or to the individual kinase inhibitors
alone. The kinase inhibitors were added 1 h before the addition of
sodium arsenite. After the indicated periods of exposure to sodium
arsenite, cells were lysed, and protein and RNA were extracted. A,
HIF-1 protein levels were assessed as in Fig. 2C. B, VEGF165 mRNA
levels were determined as in Fig. 1B. C, the relative VEGF165 mRNA
expression was determined by signal intensity measurements of
VEGF165- and -actin-protected fragments on autoradiographs and sub-
sequent normalization of VEGF165 values against -actin internal con-
trol values. The values in the bar graph are the means  S.D. of the
relative VEGF165 mRNA expression of three independent experiments
in which nontreated controls were set at 100%. Significant differences
between the relative VEGF165 mRNA expression after incubation with
sodium arsenite and that of control cells are indicated by an asterisk
(p  0.05). D, phosphorylation of p44/p42 MAPK was examined as
described in Fig. 3. E, phosphorylation of c-Jun was monitored by sub-
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sult is consistent with the role of p38 as an upstream regulator
of HIF-1 protein induction by sodium arsenite. In addition,
the above data further support that regulation of HIF-1 accu-
mulation and VEGF expression by intracellular GSH in sodium
arsenite-treated OVCAR-3 cells involves modulation of p38
activity.
JNK1 and JNK2 Are Not Essential for Induction of HIF-1
Protein and VEGF164 mRNA Expression by Sodium Arsenite in
Mouse Fibroblast Cell Lines—Unfortunately, examination of
the role of JNKs in sodium arsenite-treated OVCAR-3 cells is
complicated by the lack of pharmacological agents that specif-
ically inhibit their activity. Therefore, we have examined
whether sodium arsenite can affect HIF-1 protein and VEGF
mRNA levels in two mouse fibroblast cell lines that were defi-
cient of Jnk1 and Jnk2. We also analyzed a mouse fibroblast
cell line in which one of the four Jnk allelles, a Jnk1 allele, was
wild type. The lack of JNK activity in the two Jnk1/ Jnk2/
fibroblast cell lines was confirmed by Western blotting demon-
strating the absence of Ser73-phosphorylated c-Jun proteins in
extracts of sodium arsenite-treated cells (Fig. 6A). In contrast,
phosphorylation of c-Jun was potently induced in sodium ar-
senite-treated Jnk1/ Jnk2/ cells (Fig. 6A). As can be seen
in Fig. 6B, a clear induction of HIF-1 protein was observed in
the two Jnk1/ Jnk2/ cell lines after 4 and 8 h of exposure
to 100 M sodium arsenite. The increase in the level of HIF-1
protein upon sodium arsenite treatment was more pronounced
than that observed in Jnk1/ Jnk2/ fibroblasts. In all three
cell lines, the levels of HIF-1 protein were highest after 4 h of
treatment with sodium arsenite.
The effect of sodium arsenite on the levels of VEGF164 mRNA
in these cell lines was determined in parallel by the RNase
protection assay. As can be seen in Fig. 6B, a VEGF164-pro-
tected fragment with the expected size of 195 nucleotides and a
low signal intensity was detected in nontreated Jnk1/
Jnk2/ as well as in Jnk1/ Jnk2/ fibroblasts. Protection
of a 151-nucleotide -actin fragment was also observed in all
three cell lines. The VEGF164- and -actin-protected fragments
were not detected after hybridization of the antisense probes to
control tRNA. In addition, two other protected fragments were
visualized which were smaller in size. The protection of these
fragments was specific and, although not easily explained, may
also be caused by hybridization by -actin mRNAs. The levels
of VEGF164 mRNA in the two Jnk1
/ Jnk2/ cell lines were
increased 3–4-fold after 4 h of treatment with 100 M sodium
arsenite. In Jnk1/ Jnk2/ fibroblasts, induction of VEGF
mRNA expression by sodium arsenite was also detectable, but
was less pronounced (2-fold). Elevated levels of VEGF164
mRNA were still observed after 8 h of exposure to arsenite in
all three cell lines. In summary, our results in mouse fibroblast
cell lines demonstrate that induction of HIF-1 protein and
VEGF mRNA levels by sodium arsenite is not restricted to
FIG. 5. Effect of GSH, NAc, and BSO pretreatment on induc-
tion of p38 phosphorylation by sodium arsenite in OVCAR-3
cells. A, OVCAR-3 cells were exposed to 100 M sodium arsenite in the
absence or presence of 10 or 20 mM GSH or 10 or 20 mM NAc. GSH and
NAc were added 1 h before the addition of sodium arsenite. In addition,
cells were exposed to 20 mM GSH and 20 mM NAc alone. After an 8-h
exposure to sodium arsenite, whole cell extracts were prepared. HIF-1
protein levels and phosphorylation of p38 were assessed by subjecting
100 g of protein to SDS-gel electrophoresis (7.5% gel) followed by
Western blotting with a HIF-1-directed antiserum or with a phospho-
p38 antiserum. For assessing total protein levels of p38, the blot was
stripped and reprobed with an antiserum recognizing both nonphospho-
rylated and phosphorylated forms of p38. B, OVCAR-3 cells were ex-
posed to 30 M sodium arsenite in the absence or presence of 500 M
BSO. BSO was added 16 h before the addition of sodium arsenite. Cells
were also exposed to 500 M BSO alone. After 4, 6, and 8 h of exposure
to sodium arsenite, whole cell extracts were prepared. HIF-1 protein
levels and the phosphorylation of p38 were assessed as in A.
FIG. 6. Effect of sodium arsenite on HIF-1 protein and/or
VEGF164 mRNA levels in Jnk1- Jnk2-deficient mouse fibroblast
cell lines. Jnk1/ Jnk2/ and Jnk1/ Jnk2/ mouse fibroblast cell
lines were treated with 100 M sodium arsenite for the indicated time
periods before cells were lysed and protein and total RNA were ex-
tracted. A, c-Jun phosphorylation and HIF-1 protein levels were as-
sessed as in Figs. 4E and 2C, respectively. B, VEGF164 mRNA levels
were examined by the RNase protection assay. Total RNA was hybrid-
ized to murine VEGF164 and -actin antisense probes. t-RNA (lane T)
was hybridized as a negative control. The 195-nucleotide fragment
protected by the mRNAs of VEGF164 is indicated. Hybridization of
-actin mRNAs to the -actin antisense probe resulted in the protection
of three different fragments, including the expected fragment of 151
nucleotides (indicated by an arrow, see text below). The full-length
VEGF164 and -actin antisense probes are shown in the two leftmost
lanes. The histogram indicates the relative VEGF165 mRNA expression
in sodium arsenite-treated cells in which nontreated control cells (T 
0) were set at 100%. Quantification was performed by signal intensity
measurements of VEGF164 and -actin (151-nucleotide)-protected frag-
ments on the autoradiograph of the RNase protection experiment
shown and subsequent standardization of VEGF164 values against -ac-
tin internal control values. The experiments in A and B are represent-
ative of three independent ones with similar results.
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human ovarian cancer cells. More importantly, the data sug-
gest that JNK1 and JNK2 are not essential for these effects.
HIF-1 Protein Is Translocated to the Nucleus in Sodium
Arsenite-treated OVCAR-3 Cells—So far, it is unclear whether
induction of HIF-1 protein by sodium arsenite leads to the
formation of functional HIF-1. Because the translocation of
HIF-1 to the nucleus is an important regulatory event in the
activation of HIF-1, we first examined the subcellular localiza-
tion of HIF-1 in nontreated and sodium arsenite-treated
OVCAR-3 cells. Because hypoxia has been shown to induce
efficient nuclear translocation of HIF-1 in several cell types
(20), we assessed the subcellular distribution of HIF-1 in
hypoxic OVCAR-3 cells as a control. Cytoplasmic and nuclear
protein fractions were extracted from nontreated OVCAR-3
cells and from cells exposed to 100 M sodium arsenite or
hypoxia (1% O2) for 6 h, and identical amounts of protein
extract were subjected to SDS-PAGE and Western blotting. In
addition, whole cell extracts were prepared and analyzed in
parallel. Fig. 7 shows that a low level of HIF-1 protein expres-
sion was detected in whole cell extracts of nontreated OVCAR-3
cells and that the level of HIF-1 protein was potently induced
upon exposure to sodium arsenite as well as to hypoxia (34). A
low level of HIF-1 protein was observed in the nuclear fraction
but not in the cytoplasmic fraction of nontreated OVCAR-3
cells. Much higher levels of HIF-1 were observed in the nu-
clear fractions as well as in the cytoplasmic fractions of
OVCAR-3 cells that were exposed to sodium arsenite and hy-
poxia. As a control for the fractionation procedure, we also
analyzed the levels of proteins with a known subcellular local-
ization (Fig. 7). As assessed in whole cell extracts, the levels of
the cytoplasmic proteins Raf-1 and -actin the nuclear proteins
topoisomerase I and p53 (mutant conformation) were unaf-
fected by treatment with sodium arsenite and hypoxia. Raf-1
and -actin were indeed present primarily in the cytoplasmic
fractions, whereas topoisomerase I and p53 were detected
mainly in the nuclear fractions. These control tests confirmed
that the fractionation procedure was valid. Altogether, these
data strongly indicate that HIF-1 is transported to the nu-
cleus in nontreated OVCAR-3 cells and that HIF-1 protein
accumulates in the nucleus and in the cytoplasm of OVCAR-3
cells upon exposure to sodium arsenite and hypoxia.
Induction of HIF-1 Protein by Sodium Arsenite May Not
Lead to the Formation of Functional HIF-1 in OVCAR-3
Cells—To examine further the functional activity of HIF-1
upon sodium arsenite treatment, OVCAR-3 cells were tran-
siently transfected with a 5xHREpGL3 luciferase reporter gene
construct containing five HRE binding sites from the human
VEGF promoter in front of the SV40 minimal promoter. The
empty pGL3 promoter construct, containing only the SV40
minimal promoter in front of the luciferase gene, was trans-
fected as a negative control. We also transfected a 5xjun2pGL3
reporter construct, which contains five copies of the jun2 ele-
ment from the c-jun promoter in front of the SV40 minimal
promoter. The jun2 element binds c-Jun/ATF-2 heterodimers
and is suggested to mediate induction of c-jun gene expression
by agents that induce different types of cellular stress, includ-
ing sodium arsenite (54, 55). As mentioned earlier, c-Jun is a
substrate of JNKs, whereas ATF-2 is phosphorylated and acti-
vated by JNKs as well as by p38 (26). Because c-jun mRNA
levels were elevated in sodium arsenite-treated OVCAR-3 cells
(data not shown), we transfected the 5xjun2pGL3 reporter
construct as a positive control.
As can be seen in Fig. 8, the 5xHREpGL3 construct was not
induced by 50 and 100 M sodium arsenite as measured after
6 h of exposure. To exclude the possibility that the 5xHREpGL3
construct was not functional, transfected OVCAR-3 cells were
exposed for the same period of 6 h to hypoxia in parallel. Note
that HIF-1 protein expression was strongly induced after 6 h
of exposure to hypoxia as well as after 6 h of exposure to 100 M
sodium arsenite (Fig. 7). In agreement with findings in other
cell types, the expression of the 5xHREpGL3 reporter gene was
significantly greater (7-fold) than that of the parental pGL3
construct in hypoxic OVCAR-3 cells. This suggests that the
5xHREpGL3 construct is functional in mediating transcrip-
tional responses through HIF-1. The 5xjun2pGL3 construct
was induced 2-fold after treatment with 50 and 100 M so-
dium arsenite. This activation is actually 3-fold when normal-
ized for the activity of the parental pGL3 construct under the
same conditions. Although the kinetics of activation of c-Jun/
ATF-2 and HIF-1 upon sodium arsenite treatment may differ,
our findings with the 5xjun2pGL3 construct suggest that the
assay conditions used allow detection of increased expression of
pGL3 reporter constructs in arsenite-treated OVCAR-3. Alto-
gether, these data indicate that induction of HIF-1 protein by
sodium arsenite may not lead to the formation of functional
HIF-1 in OVCAR-3 cells.
FIG. 7. Determination of the localization of HIF-1 in non-
treated and hypoxia- or sodium arsenite-treated OVCAR-3 cells
by biochemical subcellular fractionation. OVCAR-3 cells were ei-
ther not treated or exposed to 1% oxygen (hypoxia) or 100 M sodium
arsenite under normoxia for 6 h. Cytoplasmic and nuclear fractions as
well as whole cell extracts were prepared, and 100 g of protein was
subjected to SDS-gel electrophoresis (7.5% gel) and Western blotting
with antisera directed against HIF-1, -actin, Raf-1, topoisomerase I,
and p53.
FIG. 8. Induction of HIF-1 protein by sodium arsenite does
not result in HIF-1-mediated transcriptional activation.
OVCAR-3 cells were transiently transfected in duplicate wells of six-
well culture plates with 0.5 g of the indicated pGL3-luciferase reporter
constructs together with 0.25 g of pCMVLacZ and 2.0 g of pUC19
carrier DNA (per well). pCMVLacZ was cotransfected to correct for a
variable transfection efficiency. 40 h after transfection, cells were left
untreated or exposed to 50 or 100 M sodium arsenite or 1% oxygen
(hypoxia) for an additional period of 6 h. The relative luciferase activity
in the histogram represents the mean luciferase (RUL)/-galactosidase
ratio/g of total protein/min  S.D. of duplicate extracts. Three inde-
pendent experiments were performed with similar outcome. The results
of one of them are shown.
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HIF-1 Is Not Essential for Induction of VEGF Expression by
Sodium Arsenite in Mouse Fibroblasts—To examine further the
role of HIF-1 in sodium arsenite-induced VEGF mRNA expres-
sion, we have studied the effect of this agent on VEGF mRNA
expression in a wild type and a HIF-1-deficient mouse fibro-
blast cell line (39, 56). As shown in the RNase protection assay
in Fig. 9, unstimulated HIF-1/ as well as HIF-1/ fibro-
blasts express a very low level of VEGF164 mRNA. After 4 h of
exposure to sodium arsenite, VEGF164 mRNA levels were ele-
vated 2.5-fold in HIF-1/ cells. In HIF-1/ cells, the
increase in VEGF164 mRNA at this time point was even higher,
3.5-fold. In both cell types, the -actin mRNA levels were not
altered upon sodium arsenite treatment. These findings in
mouse fibroblasts strongly suggest that HIF-1() does not play
a role in the up-regulation of VEGF mRNA expression by
sodium arsenite and support our suggestive data in OVCAR-3
cells that induction of HIF-1 protein by sodium arsenite does
not result in the generation of functional HIF-1.
DISCUSSION
We have demonstrated previously that sodium arsenite in-
duces HIF-1 protein as well as VEGF mRNA and protein
expression in the human ovarian cancer cell lines OVCAR-3
and H134 (34). Here, we show that 50 and 100 M arsenic
trioxide, an experimental anticancer agent, exerts the same
effects in OVCAR-3 cells. Although treatment of OVCAR-3 cells
with 10 M arsenic trioxide for a relatively long period of
exposure (24 h) did not influence HIF-1 protein levels, a weak
elevation was observed in the expression of VEGF165 mRNA
(1.5-fold). The levels of VEGF protein in conditioned medium
and in cell lysate were increased 3- and 2-fold, respectively.
These findings suggest that at low, clinically achievable con-
centrations of arsenic trioxide, ovarian cancer cells may re-
spond with up-regulation of VEGF protein.
The finding that arsenic trioxide induces HIF-1 protein and
VEGF expression was not unexpected because different arsenic
compounds containing trivalent arsenic have been shown to
exert similar biological effects (49). At least part of these effect
are believed to be caused by the ability of trivalent arsenic to
bind to SH groups of important cellular (signaling) proteins.
Both sodium arsenite and arsenic trioxide can activate PI3K
and/or the MAPK family members p44/p42 MAPK, SAPKs/
JNKs, and p38 (48, 49). We demonstrated that these kinases
were indeed activated by sodium arsenite in OVCAR-3 cells.
Our experiments with the PI3K inhibitor wortmannin and the
p44/p42 MAPK inhibitor PD98059 strongly suggest that so-
dium arsenite-induced HIF-1 protein and VEGF mRNA ex-
pression are independent of PI3K/Akt-1 and p44/p42 MAPK.
Interestingly, phenylarsine oxide, another trivalent arsenic
compound, can also induce HIF-1 protein through a PI3K/
Akt-1-independent mechanism (57).
Recently, it was suggested that the transcription factor c-Jun
cooperates with HIF-1 in the activation of VEGF and that
JNKs mediate this activation by phosphorylating c-Jun on
Ser63 and Ser73 (23). We showed induction of HIF-1 protein
and VEGF165 mRNA in immortalized Jnk1
/ Jnk2/ and
Jnk1/ Jnk2/ mouse fibroblast cell lines by sodium arsen-
ite, which did not involve c-Jun phosphorylation on Ser63 and
Ser73. Thus, our data provide strong evidence that JNK activity
is not essential for the effects of sodium arsenite on HIF-1
and VEGF.
The p38 MAPK inhibitors SB202190 and SB203580 com-
pletely abolished induction of HIF-1 protein and VEGF165
mRNA expression by sodium arsenite in OVCAR-3 cells. A role
of p38 as an upstream activator in the effects of sodium arsen-
ite on HIF-1 and VEGF was supported by additional observa-
tions. First, activation of p38 was observed after 1 h of exposure
to sodium arsenite and clearly preceded the induction of
HIF-1 protein and VEGF165 mRNA levels (observed after 4
and 2 h, respectively) (34). Second, we found p38 kinase acti-
vation as well as HIF-1 protein and VEGF165 mRNA expres-
sion to be co-modulated by the level of intracellular GSH (34).
Elevation of intracellular GSH by pretreatment with GSH or
NAc (a precursor for GSH) inhibited the effects of sodium
arsenite on HIF-1 protein and VEGF165 mRNA expression in
OVCAR-3 cells, whereas depletion of intracellular GSH by BSO
showed the reverse (34). We demonstrated here that pretreat-
ment with GSH, NAc, and BSO influenced the effects of sodium
arsenite on p38 activity in the same manner. Thus, p38 may act
as a mediator in the modulation of HIF-1 accumulation and
VEGF expression by intracellular GSH. Third, we have tran-
sient cotransfected OVCAR-3 cells with an expression vectors
containing either a puromycin resistance gene or a gene encod-
ing an unphosphorylatable dominant-negative mutant of p38
(DNp38). As assessed by real time quantitative PCR, induction
of VEGF165 mRNA by sodium arsenite after 3 days of selection
with puromycin was partly inhibited (20–40%) upon cotrans-
fection of DNp38 in three independent experiments. The par-
tial inhibition is likely the result of suboptimal selection of
transfected cells with puromycin. Upon stable cotransfection,
19 puromycin-resistant OVCAR-3 clones did not show detect-
able expression of DNp38, indicating that overexpression of
DNp38 may inhibit OVCAR-3 cell growth. For further studies,
the generation of OVCAR-3 cells with inducible expression of
DNp38 may be required.
Although a role for p38 in the regulation of HIF-1 protein
levels under normoxia has been suggested in some studies, this
kinase has mainly been implicated in the regulation of HIF-1
transactivation (25, 29). The mechanism by which p38 exerts
its effect on HIF-1, however, is still unclear. We have provided
evidence that sodium arsenite induces the level of HIF-1
protein by inhibiting its degradation (34). The degradation of
HIF-1 is controlled by a small domain of 200 amino acids
(amino acids 401–603), called the oxygen-dependent degrada-
tion domain (17). Interestingly, this oxygen-dependent degra-
dation domain contains three serine residues (at positions 581,
589, and 594) which may be putative targets for direct phos-
phorylation by p38. The oxygen-dependent degradation domain
mediates the interaction of HIF-1 with the tumor suppressor
FIG. 9. Effect of sodium arsenite on VEGF164 mRNA levels in
HIF-1/ and HIF-1/ mouse fibroblast cell lines. HIF-1/
and HIF-1/ mouse fibroblast cell lines were treated with 100 M
sodium arsenite for the indicated time periods before cells were lysed
and total RNA was extracted. VEGF164 mRNA levels were examined by
the RNase protection assay as in Fig. 6B.
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protein von Hipple Lindau (pVHL) under normoxic conditions
(58). pVHL is part of a multiprotein complex possessing asso-
ciated E3 ubiquitin-ligase activity and is thought to target the
degradation of HIF-1 (58, 59). Phosphorylation of Ser581,
Ser589, or Ser594 by p38 may disrupt or prevent the formation of
the HIF-1pVHL complex. It is, however, questionable
whether HIF-1 is a direct target for p38 in sodium arsenite-
treated OVCAR-3 cells. Activation of p38 already occurs after
1 h of sodium arsenite treatment, whereas HIF-1 protein
accumulation is not detectable until 4 h (34). This suggests that
p38 may regulate the HIF-1 protein indirectly, through phos-
phorylation of other factors. A possible candidate is FK506
binding protein-rapamycin-associated protein (FRAP), an ef-
fector of Akt, which may be activated by sodium arsenite in a
p38-dependent manner (60). FRAP has been suggested to me-
diate hypoxia- and growth factor-induced HIF-1 protein ex-
pression (6).
The finding that up-regulation of HIF-1 protein as well as
VEGF mRNA by arsenite is blocked by p38 kinase inhibitors
would support that induction of VEGF expression is mediated
by HIF-1. Elevation of VEGF mRNA expression in sodium
arsenite-treated OVCAR-3 cells, however, was detected at ear-
lier time points (after 2 h) than HIF-1 protein stabilization
(after 4 h) (34). Moreover, exposure of OVCAR-3 cells to sodium
arsenite did not result in transcriptional activation of a 5xHRE-
dependent reporter gene in a transient transfection assay. Fur-
thermore, treatment of OVCAR-3 with low concentrations of
arsenic trioxide also up-regulated VEGF mRNA expression in
the absence of a detectable change in the level of HIF-1
protein. Taken together, these data indicate that up-regulation
of VEGF expression by arsenite and arsenic trioxide is medi-
ated by other factors than HIF-1. This is supported by experi-
ments in HIF-1/ and HIF-1/ mouse fibroblast cell lines,
demonstrating that elevation of VEGF mRNA levels upon so-
dium arsenite treatment is even slightly higher in HIF-1/
cells than in HIF-1/ cells.
It is unclear why HIF-1 is not functional in sodium arsenite-
treated OVCAR-3 cells. Our results from subcellular fraction-
ation experiments showing that HIF-1 protein is clearly de-
tectable in nuclear cell fractions of sodium arsenite-treated
OVCAR-3 cells suggest that HIF-1 protein is properly trans-
located to the nucleus. It remains to be explored whether
HIF-1 can dimerize to HIF-1 and whether this complex is
able to bind to DNA and to transcriptional coactivators. Several
studies suggest that the DNA binding activity of HIF-1 and its
interactions with transcriptional coactivators is dependent on
its redox state (21, 22, 61). Addition of sulfhydryl-reactive
agents to extracts of hypoxic cells can inhibit HIF-1 DNA
binding (61). These agents can also inhibit the binding of
HIF-1 to coactivator(s) (21). Possibly, arsenic agents inhibit
the binding of HIF-1 to DNA or to coactivators through direct
interaction with cysteine residues. The former hypothesis is
supported by the finding that HIF-1 protein induction by
phenylarsine oxide does not result in the formation of an active
HIF-1 DNA-binding complex (57). In agreement with our re-
sults on sodium arsenite, this compound did also not provoke
HRE-dependent reporter gene activation (57).
Recently, evidence was provided that VEGF mRNA can be
stabilized in response to p38 activation under normoxic condi-
tions (62). Experiments with the transcription inhibitor actino-
mycin D suggested, however, that induction of VEGF mRNA
levels by sodium arsenite is at the transcriptional level (34).
Besides the HRE, the VEGF promoter contains binding sites
for several other transcription factors that can mediate tran-
scriptional activation of VEGF in a HIF-1-independent manner
under normoxic conditions (63, 64). As a first attempt to iden-
tify the transcription factors that mediate sodium arsenite-
induced VEGF expression in OVCAR-3 cells, we performed
transient transfection assays with luciferase reporter con-
structs containing the full-length VEGF promoter (2274/
379) (11). Although the expression of this reporter construct
was inducible by hypoxia in OVCAR-3 cells, we have never
observed any activation of this reporter by sodium arsenite.
Additional experiments are required to establish whether the
effect of sodium arsenite on VEGF expression is the result of
transcriptional activation or of mRNA stabilization. Further
investigation of the mechanism that mediates sodium arsenite-
induced VEGF expression and of the exact role of p38 in this
effect will provide important knowledge on the regulation of
VEGF expression under conditions of oxidative stress.
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